|1.||Kumar, Rakesh: 4 articles (01/2010 - 04/2008)|
|2.||Kahana, Jason A: 3 articles (02/2009 - 04/2008)|
|3.||Leber, Jack D: 2 articles (03/2009 - 04/2008)|
|4.||Choudhry, Anthony E: 2 articles (03/2009 - 04/2008)|
|5.||Heerding, Dirk A: 2 articles (03/2009 - 04/2008)|
|6.||Minthorn, Elisabeth A: 2 articles (03/2009 - 04/2008)|
|7.||Eberwein, Derek J: 2 articles (01/2009 - 04/2008)|
|8.||Zhang, Shu-Yun: 2 articles (01/2009 - 04/2008)|
|9.||Neri, Luca M: 1 article (03/2015)|
|10.||Martelli, Alberto M: 1 article (03/2015)|
01/15/2010 - "Interestingly, GSK690693 was most effective in delaying tumor progression in Lck-MyrAkt2 mice expressing a membrane-bound, constitutively active form of Akt. "
01/15/2010 - "These results suggest that GSK690693 or other Akt inhibitors might have therapeutic efficacy in human cancers with hyperactivated Akt and/or a dependence on Akt signaling for tumor progression."
01/15/2010 - "We used genetically defined mouse models that develop spontaneous tumors exhibiting activated Akt to determine if Akt inhibition by GSK690693 is effective in the treatment of cancer. "
01/15/2010 - "The broad long-term objective of this project was to use preclinical cancer models with precisely defined genetic lesions to elucidate the efficacy of targeting Akt with GSK690693. "
03/01/2009 - "We have previously disclosed identification of the AKT inhibitor GSK690693, which has been evaluated in clinical trials in cancer patients. "
|2.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
06/01/2014 - "By applying the Chou-Talalay method, low concentration of GANT58 induced T-ALL cell death in a synergism fashion with perifosine or GSK690693 when used simultaneously. "
03/30/2015 - "This pathway is currently under clinical trials with small molecules inhibitors (SMI).To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine.In"
04/01/2008 - "Daily administration of GSK690693 produced significant antitumor activity in mice bearing established human SKOV-3 ovarian, LNCaP prostate, and BT474 and HCC-1954 breast carcinoma xenografts. "
01/15/2010 - "We tested the in vivo effects of GSK690693 in Lck-MyrAkt2 transgenic mice that develop lymphomas, heterozygous Pten(+/-) knockout mice that exhibit endometrial tumors, and TgMISIIR-TAg-DR26 mice that develop ovarian carcinomas, all of which exhibit hyperactivation of Akt. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
02/19/2009 - "AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines."
02/19/2009 - "Fifty-five percent of all cell lines tested were sensitive to AKT inhibitor (EC(50)<1 microM), with acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, and Burkitt lymphoma showing 89%, 73%, and 67% sensitivity to GSK690693, respectively. "
|5.||Osteosarcoma (Osteogenic Sarcoma)
|1.||D 21266 (perifosine)
|7.||14-3-3 Proteins (14-3-3 Protein)
|1.||Heterologous Transplantation (Xenotransplantation)